Nephros Inc (NEPH)

$2.11

-0.06

(-2.76%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $2.11
    $2.19
    $2.11
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.65%

    Upside

    3.65%

    downward going graph
  • $1.32
    $4.04
    $2.11
    downward going graph

    37.44%

    Downside

    52 Weeks Volatility :67.33%

    Upside

    47.77%

    downward going graph

Returns

PeriodNephros IncIndex (Russel 2000)
3 Months
0.96%
0.0%
6 Months
-40.56%
0.0%
1 Year
50.71%
0.0%
3 Years
-77.07%
-19.4%

Highlights

Market Capitalization
22.9M
Book Value
$0.78
Earnings Per Share (EPS)
-0.14
PEG Ratio
0.0
Wall Street Target Price
4.75
Profit Margin
-10.23%
Operating Margin TTM
-5.68%
Return On Assets TTM
-8.32%
Return On Equity TTM
-16.84%
Revenue TTM
14.1M
Revenue Per Share TTM
1.35
Quarterly Revenue Growth YOY
-4.7%
Gross Profit TTM
4.7M
EBITDA
-1.3M
Diluted Eps TTM
-0.14
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.03
EPS Estimate Next Year
0.04
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
-0.01

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Nephros Inc(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
6
Hold
1
1
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 125.12%

Current $2.11
Target $4.75

Technicals Summary

Sell

Neutral

Buy

Nephros Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nephros Inc
Nephros Inc
4.46%
-40.56%
50.71%
-77.07%
-67.7%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
5.19%
21.07%
30.88%
42.93%
154.91%
Resmed Inc.
Resmed Inc.
-4.75%
14.89%
-7.36%
-20.41%
64.31%
Becton, Dickinson And Company
Becton, Dickinson And Company
-3.21%
-2.18%
-12.4%
-6.58%
-8.62%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-3.26%
-8.41%
-16.06%
-14.7%
158.45%
Alcon Ag
Alcon Ag
0.64%
13.85%
6.56%
30.19%
50.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nephros Inc
Nephros Inc
NA
NA
0.0
-0.03
-0.17
-0.08
NA
0.78
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
71.38
71.38
7.13
6.29
0.16
0.08
NA
39.37
Resmed Inc.
Resmed Inc.
31.37
31.37
1.75
7.73
0.22
0.12
0.01
31.52
Becton, Dickinson And Company
Becton, Dickinson And Company
49.52
49.52
1.34
13.04
0.05
0.03
0.02
88.74
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
41.68
41.68
6.72
7.76
0.21
0.11
0.0
36.72
Alcon Ag
Alcon Ag
42.7
42.7
4.59
3.07
0.05
0.02
0.0
42.13
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nephros Inc
Nephros Inc
Buy
$22.9M
-67.7%
NA
-10.23%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$147.6B
154.91%
71.38
27.16%
Resmed Inc.
Resmed Inc.
Buy
$30.0B
64.31%
31.37
20.91%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.0B
-8.62%
49.52
6.76%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$23.2B
158.45%
41.68
19.42%
Alcon Ag
Alcon Ag
Buy
$44.5B
50.52%
42.7
10.96%

Insights on Nephros Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 3.25M → 3.52M (in $), with an average increase of 7.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -654.0K → -169.0K (in $), with an average increase of 287.0% per quarter

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 42.9% return, outperforming this stock by 120.0%

Institutional Holdings

  • Wexford Capital LP

    34.15%
  • Bard Associates Inc

    1.70%
  • Vanguard Group Inc

    1.67%
  • Geode Capital Management, LLC

    0.67%
  • HighTower Advisors, LLC

    0.55%
  • Renaissance Technologies Corp

    0.39%

Company Information

nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil

Organization
Nephros Inc
Employees
31
CEO
Mr. Robert Banks
Industry
Medical Specialties

FAQs